Company’s Breast AI Suite of deep-learning breast
cancer detection, density assessment and risk evaluation tools showcased at ECR


NASHUA, N.H. – March 1, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced new real-world clinical evidence to be presented at the
European Congress of Radiology (ECR) 2023 meeting confirms ProFound AI® boosts
radiologists’ efficiency and accuracy. The Company is also showcasing its
Breast AI Suite of deep-learning breast cancer detection, density assessment
and risk evaluation tools in booth #AI-14 (Expo X1) at the meeting, which is
taking place in Vienna from March 1-5.


 “At ECR this year,
we are pleased to again see physicians share their real-world clinical experience
and evidence that iCAD’s AI Breast Suite has a positive impact on cancer detection
and women’s lives. Our unique AI solutions are
clinically proven to assist clinicians in daily practice to detect more
cancers, evaluate breast density, and identify women at high risk of developing
breast cancer in the short-term,” said
Michele Debain, Senior Vice
President and General Manager, Europe, Middle East, Africa, Asia Pacific.


“iCAD’s comprehensive suite of breast AI solutions offers
clinically proven benefits to clinicians and patients alike,” said Stacey
Stevens, President and CEO of iCAD, Inc. “A growing number of leading imaging
facilities worldwide trust our technologies to detect cancer and stop it in its
tracks – streamlining workflow, improving accuracy, and personalizing results
like never before.”


In a research presentation session on Friday, March 3
from 16:00-17:30 CET, Kathy Schilling, MD, Medical Director, Christine E. Lynn
Women’s Health & Wellness Institute, Boca Raton Regional Hospital, USA, will
present findings from a study titled “Real-world breast cancer screening
performance with digital breast tomosynthesis before and after implementation
of an artificial intelligence detection system.” After comparing the performance
of nine dedicated breast radiologists reading screening digital breast
tomosynthesis (DBT) exams two years before and two years after adopting
ProFound AI for DBT, researchers found ProFound AI helped radiologists find
1.31 more cancers per 1,000 screening exams for a 23% relative increase in
cancer detection rate, without increasing the rate of recalls.


“After using ProFound AI for more than two years in daily
practice, we have found not only marked improvements in efficiency and
performance, but also tremendous improvements in cancer detection rates. This
means we are finding more cancers and reading cases more accurately, without
increasing the rate of false positives and unnecessary callbacks,” said Dr.
Schilling. “ProFound AI also empowers our team to read cases faster and with
more confidence. It’s like having another expert looking at the images right by
your side.”


Studies demonstrating the clinical benefits of ProFound AI® for 2D
Mammography and ProFound AI® Risk will also be presented at ECR. Initial
results from these studies were recently highlighted at the Radiological
Society of North America (RSNA) Annual Meeting in Chicago late last year.


On Thursday, March 2, iCAD will also host an “AI After
Dark” dinner and cocktail event, featuring renowned leaders in breast imaging AI
who will discuss how iCAD’s Breast AI Suite has enhanced clinical practice and
patient care at their facilities. Featured presenters include:

  • Kathy Schilling, MD, Medical Director, Christine
    E. Lynn Women’s Health & Wellness Institute, Boca Raton Regional Hospital,
    Florida, USA
  • Axel Gräwingholt, MD, Radiologie am Theater,
    Paderborn, Germany

To learn more about iCAD’s presence at ECR or RSVP for an
event, please visit:


About iCAD, Inc.


Headquartered in Nashua, NH, iCAD® is a global medical technology
leader providing innovative cancer detection and therapy solutions. For more
information, visit


Forward-Looking Statements


Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, including statements about the expansion of
access to the Company’s products, improvement of performance, acceleration of
adoption, expected benefits of ProFound AI®, the benefits of the Company’s
products, and future prospects for the Company’s technology platforms and
products. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance, or achievements of the Company to be materially different from any
future results, performance, or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited, to the
Company’s ability to achieve business and strategic objectives, the willingness
of patients to undergo mammography screening in light of risks of potential
exposure to Covid-19, whether mammography screening will be treated as an
essential procedure, whether ProFound AI will improve reading efficiency,
improve specificity and sensitivity, reduce false positives and otherwise prove
to be more beneficial for patients and clinicians, the impact of supply and
manufacturing constraints or difficulties on our ability to fulfill our orders,
uncertainty of future sales levels, to defend itself in litigation matters,
protection of patents and other proprietary rights, product market acceptance,
possible technological obsolescence of products, increased competition,
government regulation, changes in Medicare or other reimbursement
policies, risks relating to our existing and future debt obligations,
competitive factors, the effects of a decline in the economy or markets served
by the Company; and other risks detailed in the Company’s filings with the
Securities and Exchange Commission. The words “believe,” “demonstrate,”
“intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,”
“seek,” and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in this release.
For additional disclosure regarding these and other risks faced by iCAD, please
see the disclosure contained in our public filings with the Securities and
Exchange Commission, available on the Investors section of our website at and on the SEC’s website at






Jessica Burns, iCAD  



Investor Inquiries:

iCAD Investor Relations